EHA 2024 – Shattuck reassurances fall on deaf ears
More details on cardiovascular events with the group’s anti-CD47 project comforted analysts, but shares still fell 10%.
EHA 2024 – Syndax sets up another menin inhibitor battle
Combination efficacy looks similar to Kura’s, but adverse events with revumenib could raise concerns again.
EHA 2024 – In8bio bets on a registrational plan
The group's enthusiasm is backed by an academic trial of INB-100 in 10 AML patients.
EHA 2024 preview – Shattuck has a heart scare
An early study of the group’s anti-CD47 project SL-172154 has seen waning efficacy, a heart attack and a death.
Glycomimetics down and out on upro miss
The company’s long-delayed pivotal trial is hit by a stronger-than-expected placebo performance.
Early tests approach for Vincerx’s conjugate revolution
The company reckons its tech could solve problems with current ADCs, but the market isn’t giving it much credit yet.
